Published in final edited form as:

Biochim Biophys Acta. 2014 December ; 1839(12): 1395–1403. doi:10.1016/j.bbagr.2014.02.008.

An Unexpected Journey: Lysine Methylation Across the Proteome

Kaitlyn E. Moore^{a,b} and Or Gozani^{a,*}

^a Department of Biology, Stanford University, Stanford, California 94305, USA

^b Department of Chemical and Systems Biology, School of Medicine, Stanford University, Stanford, California 94305, USA

Abstract

The dynamic modification of histone proteins by lysine methylation has emerged over the last decade as a key regulator of chromatin functions. In contrast, our understanding of the biological roles for lysine methylation of non-histone proteins has progressed more slowly. Though recently it has attracted less attention, ϵ -methyl-lysine in non-histone proteins was first observed over 50 years ago. In that time, it has become clear that, like the case for histones, non-histone methylation represents a key and common signaling process within the cell. Recent work suggests that non-histone methylation occurs on hundreds of proteins found in both the nucleus and the cytoplasm, and with important biomedical implications. Technological advances that allow us to identify lysine methylation on a proteomic scale are opening new avenues in the non-histone methylation field, which is poised for dramatic growth. Here, we review historical and recent findings in non-histone lysine methylation signaling, highlight new methods that are expanding opportunities in the field, and discuss outstanding questions and future challenges about the role of this fundamental post-translational modification (PTM).

Keywords

lysine methylation; non-histone methylation; proteome-wide; methylation signaling; post-translational modification

© 2014 Elsevier B.V. All rights reserved

*To whom correspondence should be addressed: ogozani@stanford.edu, (650)736-7639.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Competing interests disclosure

Stanford University has filed a preliminary patent application on the use of 3xMBT as an affinity reagent. O.G. is a co-founder of Epiccypher, Inc.

1. Introduction

Not so new: A historical perspective on non-histone methylation

As with histone methylation, non-histone methylation was discovered long before the field was prepared to study the post-translational modification. R.P. Ambler and M.W. Rees first reported the presence of ϵ -N-methyl-lysine in a natural protein in flagellin from *Salmonella typhimurium* in 1959 [1]. Five years later, Kenneth Murray reported methyl-lysine in histones. Murray based his analysis in part on comparison of the unusual amino acid he found in histones to methyl-lysine from flagellin [2]. Early reports of lysine methylation focused on chemical identification of the amino acid within a small subset of proteins, including ribosomal proteins, actin, myosin and myofibrillar proteins, and cytochrome c [3-8] reviewed in [9]. Rubisco, the most abundant protein on the planet [10], was also shown to be methylated [11].

Though today it is established that lysine methylation is a PTM, a great deal of work went into showing that the methyl group was added to lysine post-translationally, rather than directly incorporated as methyl-lysine during translation. Stocker, McDonough, and Ambler argued that methylation of flagellins occurred after lysine was incorporated into the protein because the presence of methyl-lysine was controlled by a gene other than the gene for flagellin [12]. Incorporation of radioactive methylation into methyl-lysine residues was not inhibited by puromycin, a translation inhibitor, again suggesting that methylation is a PTM [13, 14]. Finally, methyl-lysine could not be conjugated to tRNA, which would be necessary if it were to be incorporated during translation [14].

If the methyl group was incorporated post-translationally, where did it come from? Using radiolabeling experiments, it was shown that either methionine or S-adenosyl-methionine could serve as the source of the methyl group on lysine [2, 3, 14, 15]. Murray proposed that this methylation might be sequence specific [2], and by 1965, Kim and Paik argued that methylation in calf thymus nuclei was enzymatic [14]. In the years that followed, the field continued to focus on identifying new methylated proteins individually and on purifying a limited number of methylating enzymes (reviewed in [16]). As Woon Ki Paik, David C. Paik, and Sangduk Kim described, the field made little progress in identifying the biological function of this methylation [16]. Without a downstream biological outcome for lysine methylation, the broader significance of adding this moiety was unclear.

Biological insight into histone methylation was fueled by discoveries like the one from the lab of Thomas Jenuwein identifying the epigenetic regulator Suv39H1 as a histone lysine methyltransferase [17]. Notably, comparison with a known non-histone methylation pathway aided the identification of this histone methylation pathway; Rea *et al.* hypothesized that Suv39h1 might be a methyltransferase based on its homology to Rubisco large subunit methyltransferase [17, 18]. The availability of techniques to study chromatin biology allowed quick bridging of methylation events with downstream phenotypic assays. New assays for chromatin biology grew along with the field of histone methylation—for example, chromatin immunoprecipitation (ChIP) coupled with microarrays (ChIP-chip) [19-21] and more recently ChIP coupled with deep sequencing (ChIP-seq) [22, 23]. Just as Paik, Paik, and Kim pointed out that the advent of modern molecular biology opened up the

long struggling field of lysine methylation in general [16], tools for studying gene regulation and chromatin naturally shifted the focus of the field toward histones and other chromatin-related proteins. Tool development, as will be discussed later, is likely to be important for studying lysine methylation on non-histone proteins as we move forward.

2. Key examples of non-histone methylation

Non-histone methylation has experienced a moderate renaissance with the finding that several histone lysine methyltransferases also methylate other substrates (see [24] for a recent review of lysine methyltransferases (KMTs) and corresponding histone and non-histone targets). Below we describe regulatory lysine methylation on several key non-histone proteins. As the number of lysine methylation events has greatly expanded over the last few years, this review is by no means an exhaustive discussion, but rather focuses on some specific methylation events to highlight regulatory trends and concepts.

2.1. p53 methylation—p53 is a central tumor suppressor and a decision node for triggering apoptosis [25], which is regulated by lysine methylation (reviewed in [24, 26-28]). p53 methylation was first reported by Reinberg and colleagues. In 2004, they showed that Set7/Set9 monomethylates p53 at lysine 372 (p53K372me1) [29]. This methylation event was found to promote the stability of nuclear p53, expression of the p53 target p21, and DNA-damage induced p53-mediated apoptosis [29], potentially through preceding and promoting acetylation of p53 [30]. Several methylation events have also been reported to negatively regulate p53 activity. Smyd2 monomethylates p53 at lysine 370 [31]. This methylation event represses p53 activity by decreasing its ability to bind promoters of target genes [31]. Huang *et al.* proposed that K370me1 is a repressive mark due to a decrease in the fraction of total p53 bearing the mark at a target promoter upon DNA damage and because Smyd2 expression was inversely correlated with p53-target gene expression [31]. Interestingly, prior activating K372 monomethylation inhibits subsequent K370 monomethylation, but not vice versa, in part by decreasing the ability of Smyd2 to bind p53 [31]. SET8-mediated monomethylation at lysine 382 was also found to repress p53 transcriptional activation, decreasing expression of p53 target genes [32]. More recently, G9a and GLP were reported to dimethylate p53 at lysine 373 [33]. As levels of p53K373me2 do not increase with DNA damage despite a large increase in total p53 levels, this mark is postulated to repress p53 activity [33]. Consistent with this idea, knockdown of G9a and GLP increased apoptosis, with and without DNA damage [33].

p53 was the first non-histone protein for which regulatory demethylation was reported. In 2007, Berger and colleagues showed that the lysine demethylase LSD1 removes the p53K370me2 mark [34]. Dimethylation of K370 by a yet to be identified KMT activates p53 transcriptional activity through the recruitment of 53BP1, a protein involved in DNA damage signaling and initially identified as a p53 co-activator [35, 36]. LSD1 demethylation of K370me2 disrupts the interaction between p53 and 53BP1 and thus acts to repress p53 function [34].

2.2. RelA—RelA/p65 is a component of the canonical NF- κ B signaling pathway that translocates to the nucleus to bind target genes upon signaling activation. Several lysines in

RelA have been reported to be methylated, including K37, K218, K221, K310, K314, and K315 [37-41]. Levy *et al.* provided an example of regulation of NF- κ B signaling by methylation. In a biochemical screen with forty candidate KMTs, SETD6 was identified as a novel methyltransferase of the chromatin-associated fraction of the NF- κ B subunit RelA [38]. SETD6-mediated methylation of RelA at lysine 310 (RelAK310me1) rendered RelA inert and attenuated RelA-driven transcriptional programs, including inflammatory responses in primary immune cells. The ankyrin repeat from GLP – an H3K9 methyltransferase involved in transcriptional repression – functioned as a recognition motif for RelAK310me1. Under basal conditions, SETD6-dependent binding of GLP to RelAK310me1 promoted a repressed chromatin state at RelA target genes through GLP-mediated H3K9 methylation. This repressive pathway was overridden by NF- κ B activation-linked phosphorylation of RelA by PKC ζ at serine 311 (RelAS311ph), which blocked GLP binding to RelAK310me1 and drove target gene expression [38]. These series of molecular events were the first description of a lysine methylation-signaling cascade and demonstrated a new mechanism for how integrated crosstalk between modifications on transcription factors and histones can modulate gene expression programs.

2.3. Dam1—Sharon Dent and colleagues have reported the Set1-dependent methylation of Dam 1 in yeast [42, 43]. Dam1 forms part of a complex that regulates chromosome segregation, and is itself regulated through phosphorylation by the Aurora kinase Ipl1 [42]. Zhang *et al.* showed that loss of Set1 catalytic activity suppresses temperature-sensitive inactivation of Ipl1 [42]. They also found that this genetic interaction can be tied to Set1-dependent dimethylation of Dam1 at lysine 233 [42]. This methylation event interacts genetically with Ipl1 phosphorylation at nearby serine residues—K233 mutation can be rescued by subsequent mutation at S232, S234, or S235 [42]. The authors proposed that K233 methylation inhibits phosphorylation of S232 and S234 [42]. The group later showed that just as H2BK123 ubiquitination regulates Set1 methylation of H3K4, H2BK123ub is required for Set1 methylation of Dam1K233, establishing that both the histone and non-histone substrate of Set1 are regulated through the same initial histone modification pathway [43].

2.4. Spliceosomal proteins—The spliceosome is known to be a significant target of arginine methylation, which plays a role in snRNP assembly (see [44] for a review). Recent proteome-wide studies indicate that a significant portion of the spliceosome is also subject to lysine methylation [45-48]. The role of this methylation is as-yet unexplored. It is enticing to think that lysine methylation might modulate splicing through mechanisms such as spliceosome assembly or splice site selection, but experimental evidence in this area is currently lacking.

2.5. Ribosomal proteins—Methyl-lysine was discovered in ribosomal proteins of *S. cerevisiae* in 1984 [49]. Enzymes which methylate yeast ribosomal proteins were first identified in 1989 [50]. These enzymes were dubbed M23 and M32 because they methylate Y23 and Y32, respectively [50] (the enzymes are now referred to as Rkm2 and Rkm1, methylating Rpl12 and Rpl23, respectively [51]). A number of papers from Steven Clarke and colleagues describe a series of methylation events on ribosomes and the corresponding

KMTs. The KMT Rkm1 dimethylates Rpl23ab at lysine 105 and 109 [52, 53] and Rkm2 trimethylates Rpl12ab, most likely at lysine 3 (potentially at lysine 10) [54, 55]. Rpl42ab is monomethylated at lysines 40 and 55 by Rkm3 and ySET7, respectively [55]. Rkm5 monomethylates Rpl1K46 [56]. As discussed in [56], it is unclear whether these yeast methylation events translate to homologous mammalian ribosomal methylation. However, methylated ribosomes have been independently identified in mammalian samples (for example, see [45-48, 57], reviewed in [51]).

2.6. Translational elongation factors—Methylated elongation factors have been studied in bacteria, fungi, and mammalian systems since the late 1970s [51], with recent proteomic studies of lysine methylation identifying a large number of additional modified translation elongation factors [45, 48]. Though the function of elongation factor methylation is still largely unknown, in *E. coli* methylation of EF-Tu tracks growth phase and may modulate EF-Tu's GTPase activity [58] (reviewed in [51]). Amongst more recent examples, Lipson *et al.* described monomethylation of eEF1A by YHL039W (dubbed Efm1) and dimethylation of eEF1A by See1 in *S. cerevisiae* [59]. Couttas *et al.* later localized these sites of methylation to K30 and K316, respectively [60]. They also described trimethylation of EF3AK187 by YBR271W (named Efm2) [60]. For a comprehensive review of elongation factor methylation, see [51].

2.7. Heat shock proteins—Heat shock proteins represent another class of cytosolic methylated proteins. Two groups reported Smyd2-mediated HSP90 methylation [61, 62]. Abu-Farha *et al.* argued that Smyd2 methylates two sites on HSP90, the predominant one being K615 in the dimerization domain [61]. They also proposed that HSP90 might be demethylated by LSD1 [61]. Donlin *et al.* reported Smyd2-mediated monomethylation of K615 (numbered K616 in their study) [62]. They showed that Smyd2 and methylated HSP90 colocalized with titin and potentially regulate sarcomeres (and therefore muscle) through this interaction [62].

Two KMTs have been reported to methylate HSP70s: SETD1A and METTL21A/HSPA-KMT [63, 64]. Cho *et al.* reported SETD1A-dependent HSP70-K561me2 [63]. They showed that this methylated version of HSP70 localizes to chromosomes, rather than the cytoplasm, and that this methylation event may promote an association with Aurora kinase B that stimulates kinase activity [63]. Jakobsson *et al.* showed that METTL21A trimethylates the same residue in several human HSP70s [64]. Though trimethylation of K561 does not appear to alter basic HSP70 functions, it does affect the interaction of the HSP70 isoform HSPA8s with α -synuclein, which is implicated in Parkinson's disease [64]. Methylation of this conserved lysine was also observed by Cloutier *et al.*, who showed that several enzymes from METTL21A's family have lysine methylation activity [65]. Cloutier *et al.* also described methylation of several other HSP70 isoforms, as well as the proteins KIN and VCP [65].

3. Transducing non-histone methylation signals: “reader proteins”

Lysine methylation pathways are essentially signaling processes. In response to a signal, a KMT methylates a substrate. This signal is then transduced by state- and sequence-specific

effector proteins, which read out the methylation event catalyzed by the KMT and translate that methylation event into downstream responses. As might be expected, these “reader” proteins have been most extensively studied as methyl-histone binders. However, several readers have been shown to bind to methylated lysine in non-histone proteins. Below, we discuss several of the most-studied non-histone methyl-lysine binders. Examples of methylation signaling pathways are shown in Figure 1.

3.1. L3MBTL1—L3MBTL1 was originally studied as an H4K20me1/2 and H1bK26me1/2 binder [66]. L3MBTL1 binds methylated lysine through its 3 malignant brain tumor (MBT) domain repeats [66-68] (reviewed in [69]). L3MBTL1 was known to interact with a transcription regulatory complex involving Rb [66], and Saddic *et al.* showed that L3MBTL1 binds Smyd2-catalyzed Rb monomethylation at lysine 860 [70]. L3MBTL1 also interacts with SET8-catalyzed p53K382me1, leading to decreased expression of p53-regulated genes [71]. While full-length L3MBTL1 in these examples has specific biological functions, the MBT domains of L3MBTL1 appear to have very little amino acid sequence specificity [45, 66, 72].

3.2. 53BP1—p53-binding protein 1 (53BP1) was isolated in a two-hybrid screen for p53 interacting proteins [35]. 53BP1 has been reported to bind dimethylation of two residues within p53: K370 and K382 [34, 73]. At K370, 53BP1 binding is thought to function as a transcriptional co-activator at p53-target genes [34]. For K382me2, the binding of 53BP1 is proposed to serve as a molecular mechanism by which DNA double strand break signals are transduced to activate p53 during the DNA damage response [73]. The sequence surrounding K382 of p53 is very similar to that surrounding H4K20. 53BP1 and L3MBTL1 both bind to methylated H4K20 and p53K382, raising the idea that sequences in non-histone proteins have evolved to mimic histone sequences and might therefore be regulated by conserved reader domains [28, 66, 71, 73-75].

3.3. HP1—The chromodomain of HP1 was the first known methyl-lysine reader domain and helped establish the molecular mechanism and structural basis by which histone methylation marks are transduced [76-78]. The KMT G9a methylates H3K9 [79, 80] and has also been reported to methylate other residues on histones as well as non-histone substrates [79, 81-94]. Several groups therefore asked whether HP1, as a methyl-H3K9 binder, could also bind non-histone methylation at similar sequences. Sampath *et al.* found that HP1 γ interacts with G9a dependent on an intact G9a automethylation site at lysine 165 [81]. Chin *et al.* also found that mouse HP1 interacts with G9a dependent upon the K239 automethylation site [82]. Rathert *et al.* generalized this idea, showing that HP1 β can bind to methylated peptides representing G9a sites on WIZ, CDYL1, HDAC1, ACINUS, Kruppel, and G9a [83]. Expanding to a proteomic scale, Liu *et al.* assumed that HP1 β would have many binding partners and set out to describe its methyl-dependent “interactome” [47]. They found that, amongst other proteins, HP1 β binds to methylated DNA-PKcs [47].

4. Functional consequences of non-histone methylation

A recent expansion in methods for proteomic analysis has led to a large increase in the number of known methylated non-histone proteins. From larger scale “methyloomics” studies

[45-48], several cellular processes are emerging as hubs of potential regulation by lysine methylation. This information facilitates asking functional questions about what lysine methylation does on a broad scale to establish regulatory themes.

4.1. Interactions between PTMs on non-histone proteins—On histones, post-translational modifications act in a combinatorial or antagonistic manner to regulate signaling [69]. Naturally, this concept also applies to methylation of non-histone proteins. For example, crosstalk has been reported between several PTMs on p53. Huang *et al.* showed that methylation at K372 inhibits the interaction of p53 with Smdy2 and subsequent K370 methylation [31] and p53 methylation at K370 influences p53 acetylation [30].

“Methyl-phospho” switches represent a distinct class of PTM crosstalk. The classic model of a methyl-phospho switch is H3K9 methylation and S10 phosphorylation, wherein S10 phosphorylation serves to inhibit binding of HP1 to methylated K9 [17, 95, 96]. When Fischle, Wang, and Allis formally proposed the idea of methyl-phospho switches as “local binary switches,” they also suggested that the concept might extend beyond histones [97]. Similar switches exist between G9aK165 methylation and T166 phosphorylation [81] and between RelAK310 methylation and S311 phosphorylation [38]. Dam1K233 methylation also interacts with nearby phosphorylation at residues S232, S234, and S235 [42]. Another form of interaction between PTMs on non-histone proteins is through methylation “blocking,” the concept that methylation could prevent acetylation or ubiquitination (or other lysine modification) of the same residue and thus suppress outcomes associated with those PTMs [98]. However, given that it is unlikely for a lysine to be 100% methylated – and indeed methylated species are likely in the minority – it is not clear that signaling through competition of modification systems for a specific residue would be an effective mechanism.

4.2. Methylation and protein-nucleic acid interactions—Of methylated non-histone proteins identified so far, a large portion form part of a protein-nucleic acid complex (also noted in [99]). For example, the ribosome and the spliceosome, both large RNP machines, are well-represented amongst methylated proteins [45-48]. Perhaps this shouldn't be surprising, given that histones largely function in complex with a nucleic acid. This trend may give us clues as to broader regulatory functions of methylation within the cell. In his review on the subject, Steven Clarke suggested that one function of methylation of ribosomal proteins is to encourage their interaction with rRNA [100]. Clarke also notes that many non-histone methylated proteins are related to transcription, again linking the modification to proteins that interact with a nucleic acid [100].

4.3. Biophysical functions—Unlike phosphorylation and acetylation, methylation does not alter the charge of the modified residue. The methyl group constitutes a relatively small change in steric bulk and hydrophobicity of lysine side chains. These observations suggest that lysine methylation would be less likely to play a direct chemical or biophysical role in protein regulation. One possible direct role for the modification might be to increase protein stability, through mechanisms such as decreasing susceptibility to proteases and increasing heat tolerance (as discussed in [11, 56, 100-102]), potentially through promoting intra-molecular interactions that stabilize the polypeptide. Two groups have also proposed

that methylation can negatively regulate stability, citing decreased DNMT1 half-life when methylated, perhaps through a proteasome-mediated mechanism [103, 104].

5. Methods for uncovering non-histone methylation

The field of non-histone methylation faces a methods hurdle: most current studies rely on candidate-based approaches. However, recent work has focused on the problem of proteome-wide identification of methylated proteins. Two major proteomic approaches have been used: peptide and protein array-based assays, and affinity or chemical enrichment coupled with mass spectrometry.

5.1. Array-based approaches—Peptide and protein arrays have been used to identify non-histone substrates of KMTs. In the case of peptide arrays, the array often serves to define a consensus sequence for the methylation-related enzyme in question, whereas protein arrays are often used to directly test for enzymatic targets in a high-throughput manner. Albert Jeltsch and colleagues used permutation arrays of peptides based on the previously known G9a target, H3K9 [79, 80], to identify a consensus methylation sequence for G9a [83]. They then predicted potential G9a substrates using two methods: searching the proteome for proteins bearing the consensus methylation motif, and searching known G9a-interactors for a reduced “RK” motif [83]. Using this method, they identified several non-histone targets of G9a, including G9a itself, WIZ, ACINUS, CDYL1, and others [83], supplementing previous reports of non-histone G9a targets identified by lower throughput methods [81, 82]. They also found that HP1 β could bind to trimethylation at several of these non-histone sites [83]. Using this method, Jeltsch and colleagues also identified a number of new Set7/9 substrates, including MINT, IRF1, MeCP2, ZHD8, and PPARBP, amongst others [105]. Peptide arrays have also been used to describe substrate specificity for SET8 [106] and Dim-5 [107].

Short peptides represent a minimal *in vitro* target for KMTs, but might not present an appropriate recognition surface for enzymes. Protein (rather than peptide) arrays represent a potentially more physiological, yet still *in vitro*, panel of potential KMT substrates. This approach was validated in Levy *et al.*, which used Invitrogen ProtoArrays® as a substrate for methylation reactions in order to identify substrates of Set7/9 and SETD6 [108]. Several of the novel SETD6 substrates identified through the array were validated in cells [108].

5.2. Affinity enrichment coupled to mass spectrometry—Mass spectrometry (MS) is an excellent method for proteomic scale studies of PTMs. This method has significant advantages over arrays: it can identify the site, state, and stoichiometry of methylation directly and it can measure the results of *in vivo* methylation reactions representing physiological conditions. However, MS analyses are biased towards detecting the most abundant proteins, and given the relatively low abundance of methylation events, few methylation events tend to be “seen” in a given MS run. This can be circumvented in part through an enrichment step, which has been the focus of several recent method development efforts [45-48, 84, 85].

The most familiar approach for enriching a PTM is affinity enrichment using antibodies specific for the PTM but not specific to a particular amino acid sequence (“pan-specific”

antibodies). This strategy has proven successful for phosphorylation, ubiquitination, acetylation, and arginine methylation [109-112], but has been difficult to adapt to lysine methylation due to the challenge in developing high-affinity “pan-methyl” antibodies. The first attempt at using pan-methyl antibodies for enrichment before mass spectrometry analysis found only four known methylation events on two lysines, both in histones [112]. In that particular study, pull-down with the pan-lysine-methyl antibody actually led to identification of a large number of arginine methylation events [112]. Levy *et al.* subsequently tested several commercially available “pan-methyl” antibodies on arrays of post-translationally modified peptides and found cross-reactivity with other PTMs and insufficiently broad sequence specificity [108]. More recently, Bremang *et al.* compared the enrichment activity of pan-methyl antibodies with the increase in proteomic coverage from additional sample fractionation and concluded that the antibodies contributed little in the way of identifying additional methylation events [46]. The failure of commercial antibodies has prompted others to generate their own polyclonal pan-methyl antibodies. For example, Ben Garcia’s group developed polyclonal mono-, di-, and tri-methyl-lysine antibodies which enriched methylated peptides from tryptic digest of cell lysates, and found a significant number of novel methylation events [48].

A related approach employs natural methyl-lysine binding domains to affinity enrich methylated proteins. Liu *et al.* used precipitation by the chromodomain of HP1 β , coupled with mass spectrometry, to uncover the interactome of the protein and novel methyl-lysine-mediated biology. They first established the consensus binding sequence of the HP1 β chromodomain using peptide arrays, and then used this to predict methylation sites within proteins specifically precipitated by the chromodomain, validating the sites by mass spectrometry [47]. They directly identified 29 methylated HP1 β -interacting proteins [47].

Using a similar approach, Moore and Carlson *et al.* specifically precipitated proteins that bound to the 3 malignant brain tumor domain repeats (3xMBT) of the L3MBTL1 protein. Several groups had previously suggested that 3xMBT had sequence promiscuity [67, 68, 72]. Moore and Carlson *et al.* further established that while 3xMBT binds mono- and di-methyl-lysine specifically, the sequence and modifications surrounding the methylated residue had little effect on 3xMBT binding [45]. Comparison of proteins pulled-down by 3xMBT and a binding-null point mutant, 3xMBT_{D355N} [67, 68] was used to eliminate non-specific protein-protein interactions. In total, this report identified several hundred potentially methylated proteins, with methylation directly observed and validated on 26 lysines [45].

Together, these recent proteomic studies have identified RNA processing, transcription, chromatin remodeling/organization, and helicase activity, amongst others, as processes where methylation appears to play a significant role [45-48].

5.3. Chemical enrichment coupled to mass spectrometry—Rather than rely on an antibody or methyl-lysine binding domain to enrich for methylated proteins, chemical labeling methods also allow for subsequent enrichment of methylated proteins. In general, these methods functionalize the methyl-donor, S-adenosyl-methionine (SAM), with a bioorthogonally-reactive chemical moiety which is transferred to the substrate protein in

place of the methyl group. While this approach has been conducted with a ketone-functionalized donor [113], by far the most common method has been functionalizing the donor with an alkyne- or azide-containing group [84, 85, 114-116]. Transfer of either of these particular moieties is preferred because azides and alkynes react in a bioorthogonal, copper-catalyzed cycloaddition, which can later be used to attach affinity tags or other probes to the “methylated” target. Other related reactions, including copper-free, strain promoted cycloadditions, have also been used [84, 117]. (These reactions are generally referred to as “click” chemistry, though the term itself indicates a broader class of reactions.) Several native methyltransferases, including Dim5, MLL4, and SETDB1, can transfer alkyne groups to their substrates [114, 115]. However, not all native KMTs accept these cofactors [115].

To generalize this labeling method, Minkui Luo and colleagues screened a panel of alkyne-functionalized SAM analogues against a set of G9a mutants to find an active analogue-mutant pair [116]. This “bump hole” approach [118, 119] allowed them to access the activity of a protein which would not, as wildtype, accept a functionalized cofactor. After validating the concept, they then coupled the bump-hole/click approach to mass spectrometry [84]. Bump-hole mutants of the related methyltransferases G9a and GLP were given their cognate analogues in cell lysate, labeled substrates were “clicked” to a biotin conjugate, and then “methylated” substrates were precipitated with streptavidin beads for mass spectrometry analysis [84]. They identified 82 and 64 substrates, respectively, for G9a and GLP [84]. Additionally, this work helped define the separate substrate repertoires of G9a and GLP, which share several substrates (reviewed in [120])— 64 and 46 of the substrates identified by Islam *et al.* were unique, respectively [84]. In more recent work, Islam *et al.* analyzed structure-activity-relationships of active enzyme mutant/modified cofactor pairs, identifying many more potential G9a and GLP substrates [85]. For a review of chemical labeling methods used to study lysine methylation, see [121]. A comparison of methods for studying lysine methylation is summarized in Table 1 and reviewed in [98].

6. Moving forward: open questions

6.1. How many proteins are methylated? What is the specificity of various KMTs?—There are currently more than 60 predicted lysine methyltransferases and 30 predicted lysine demethylases in the human genome [122-124]. In total, recent reports have shown that hundreds of proteins may be methylated, some at multiple sites, and to different degrees (mono-, di-, tri-) at a given site [45-48, 84, 85]. It seems likely that many more methylation events will be uncovered soon. This suggests a comparison between the number of methylation events and the number of methyltransferases, and raises questions about the degree of specificity of these enzymes. How many substrates should we suspect a methyltransferase to have?

For several characterized KMTs, the answer is clearly “many”; *in vitro*, enzymes like Set7/9 and G9a are promiscuous [79-94, 105, 108] (reviewed in [24, 26, 27, 125]). For example, on protein arrays, Set7/9 methylates over 300 proteins [108]. Other KMTs appear quite specific, with only one reported target [24]. KMTs may even be specific for particular substrate states—for example, NSD2/MMSET/WHSC1 has little activity on free histones

but robust activity as an H3K36 dimethyltransferase on nucleosomes [126, 127]. However, for many KMTs and KDMs, there has been no unbiased proteomic assessment of multi-substrate potential. Methyl-regulating enzymes are currently being examined as potential therapeutic targets (reviewed in [128]), so careful analysis of substrate repertoires and potential promiscuity could have profound impact on drug development research.

If KMTs and KDMs are not especially specific, we might also raise the question of the relative biological importance of multiple methylation events catalyzed by the same KMT. For example, Set7/9 methylates multiple sites on histones, including H3K4, as well as many non-histone substrates [29, 30, 105, 108, 129, 130] reviewed in [24, 26, 27, 125] (our unpublished observations), and the biological relevance of any particular catalyzed methylation event in vivo is difficult to discern. Despite Set7/9's many reported substrates, loss of Set7/9 activity in mice has a minimal phenotype, suggesting that the combined effect of losing multiple methylation events in conjunction with compensation mechanisms will complicate predictions about in vivo phenotypes of specific methylation reactions [131, 132]. In the terminology of Erce *et al.*, we need to describe the “‘weighted’ networks” of KMT activity [98]. With respect to pharmaceutical development, understanding the relative biological functions of methylation events is necessary to ensure that the relevant methylation events are targeted for intervention.

Another question raised by the large number of global methylation sites is whether we have accounted for enough enzymes to catalyze the growing number of methylation events. Without a thorough evaluation of KMT specificity, this is difficult to assess. Might there be another family of KMTs yet unaccounted for? A core group of enzymes with well-defined SET and seven- β -strand domains currently dominate the KMT field, but enzymes bearing more distant homology or other domain structures might be KMTs. For example, the seven- β -strand METTL21-related KMT family was identified only recently, and appears to be related to arginine methyltransferases [65, 122]. The possibility that other such families may exist adds an interesting dimension to the assignment of methylated proteins to their cognate KMTs.

6.2. Methylation in transcription and translation: shared regulatory mechanisms?

Transcription and translation both appear as repeated themes amongst methylated proteins [45, 46, 48]. It is intriguing to speculate that these two fundamental processes could be regulated by similar mechanisms through lysine methylation. Comparatively little is known about the function of methylation of translation factors, but in both cases the ability of methylation to mediate protein-protein interactions could play a role in fine-tuning protein expression and activity. Even if methylation acts through different molecular functions in transcription and translation, feedback or co-regulation of the processes through regulation of the same or related KMTs presents an interesting possibility.

7. Conclusion

We now know that lysine methylation occurs broadly across the proteome—at chromatin, elsewhere in the nucleus, and in the cytoplasm. It regulates such core cellular processes as transcription and translation, influencing protein-protein and potentially protein-nucleic acid

interactions. Recent proteomic studies have developed methods to more efficiently uncover lysine methylation events, elucidating the “where” of lysine methylation. However, the locations of the methylation events themselves are only part of the story. To truly understand lysine methylation biology, we need to understand the full signaling pathways that utilize this PTM.

This will require experimental analysis of the enzymes that catalyze addition and removal of methyl marks, of the effectors that bind to methylation events, and of the direct biophysical and biochemical consequences of methylation. The ability of lysine methylation to regulate vast swathes of physiological and pathological biology provides a remarkable example of the biological utility of one small PTM.

Acknowledgements

We apologize to colleagues whose work we were not able to include due to space limitations. K.E.M. is supported by a Hubert Shaw and Sandra Lui Stanford Graduate Fellowship. This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1147470 to K.E.M. This work was supported in part by grants from the NIH to O.G. (R01 GM079641).

Abbreviations

PTM	post-translational modification
KMT	lysine methyltransferase
KDM	lysine demethylase
SAM	S-adenosyl methionine
MBT	malignant brain tumor
RNP	ribonucleoprotein
MS	mass spectrometry

Post-translational indications are indicated with protein name, site of modification, and modification type/extent, without spaces (for example, RelAK310me1 is monomethylation of lysine 310 on the protein RelA).

References

1. Ambler RP, Rees MW. Epsilon-N-Methyl-lysine in bacterial flagellar protein. *Nature*. 1959; 184:56–57. [PubMed: 13793118]
2. Murray K. The Occurrence of Epsilon-N-Methyl Lysine in Histones. *Biochemistry*. 1964; 3:10–15. [PubMed: 14114491]
3. Comb DG, Sarkar N, Pinzino CJ. The methylation of lysine residues in protein. *J Biol Chem*. 1966; 241:1857–1862. [PubMed: 5329588]
4. Huszar G, Elzinga M. Epsilon-N-methyl lysine in myosin. *Nature*. 1969; 223:834–835. [PubMed: 4240503]
5. Hardy MF, Perry SV. In vitro methylation of muscle proteins. *Nature*. 1969; 223:300–302. [PubMed: 5792725]
6. Weihing RR, Korn ED. Epsilon-N-dimethyllysine in amoeba actin. *Nature*. 1970; 227:1263–1264. [PubMed: 5212577]

7. Hardy M, Harris I, Perry SV, Stone D. Epsilon-N-monomethyl-lysine and trimethyl-lysine in myosin. *Biochem J.* 1970; 117:44P–45P.
8. DeLange RJ, Glazer AN, Smith EL. Presence and location of an unusual amino acid, epsilon-N-trimethyllysine, in cytochrome c of wheat germ and *Neurospora*. *J Biol Chem.* 1969; 244:1385–1388. [PubMed: 4304194]
9. Paik WK, Kim S. Protein methylation. *Science.* 1971; 174:114–119. [PubMed: 5119619]
10. Ellis RJ. The most abundant protein in the world. *Trends Biochem Sci.* 1979; 4:241–244.
11. Houtz RL, Stults JT, Mulligan RM, Tolbert NE. Post-translational modifications in the large subunit of ribulose biphosphate carboxylase/oxygenase. *Proc Natl Acad Sci U S A.* 1989; 86:1855–1859. [PubMed: 2928307]
12. Stocker BAD, McDonough MW, Ambler RP. A Gene Determining Presence or Absence of ϵ -N-Methyl-Lysine in *Salmonella* Flagellar Protein. *Nature.* 1961; 189:556–558.
13. Allfrey VG, Faulkner R, Mirsky AE. Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis. *Proc Natl Acad Sci U S A.* 1964; 51:786–794. [PubMed: 14172992]
14. Kim S, Paik WK. Studies on the origin of epsilon-N-methyl-L-lysine in protein. *J Biol Chem.* 1965; 240:4629–4634. [PubMed: 5846984]
15. Kerridge D. Flagellar Synthesis in *Salmonella* Typhimurium: The Incorporation of Isotopically-Labelled Amino Acids into Flagellin. *J Gen Microbiol.* 1963; 33:63–76. [PubMed: 14072837]
16. Paik WK, Paik DC, Kim S. Historical review: the field of protein methylation. *Trends Biochem Sci.* 2007; 32:146–152. [PubMed: 17291768]
17. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T. Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature.* 2000; 406:593–599. [PubMed: 10949293]
18. Klein RR, Houtz RL. Cloning and developmental expression of pea ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit N-methyltransferase. *Plant Mol Biol.* 1995; 27:249–261. [PubMed: 7888616]
19. Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I, Zeitlinger J, Schreiber J, Hannett N, Kanin E, Volkert TL, Wilson CJ, Bell SP, Young RA. Genome-wide location and function of DNA binding proteins. *Science.* 2000; 290:2306–2309. [PubMed: 11125145]
20. Iyer VR, Horak CE, Scafe CS, Botstein D, Snyder M, Brown PO. Genomic binding sites of the yeast cell-cycle transcription factors SBF and MBF. *Nature.* 2001; 409:533–538. [PubMed: 11206552]
21. Horak CE, Snyder M. ChIP-chip: a genomic approach for identifying transcription factor binding sites. *Methods Enzymol.* 2002; 350:469–483. [PubMed: 12073330]
22. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. *Cell.* 2007; 129:823–837. [PubMed: 17512414]
23. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, Euskirchen G, Bernier B, Varhol R, Delaney A, Thiessen N, Griffith OL, He A, Marra M, Snyder M, Jones S. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. *Nat Methods.* 2007; 4:651–657. [PubMed: 17558387]
24. Zhang X, Wen H, Shi X. Lysine methylation: beyond histones. *Acta Biochim Biophys Sin (Shanghai).* 2012; 44:14–27. [PubMed: 22194010]
25. Levine AJ. p53, the cellular gatekeeper for growth and division. *Cell.* 1997; 88:323–331. [PubMed: 9039259]
26. Huang J, Berger SL. The emerging field of dynamic lysine methylation of non-histone proteins. *Curr Opin Genet Dev.* 2008; 18:152–158. [PubMed: 18339539]
27. Lan F, Shi Y. Epigenetic regulation: methylation of histone and non-histone proteins. *Sci China C Life Sci.* 2009; 52:311–322. [PubMed: 19381457]
28. West LE, Gozani O. Regulation of p53 function by lysine methylation. *Epigenomics.* 2011; 3:361–369. [PubMed: 21826189]

29. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gambelin SJ, Barlev NA, Reinberg D. Regulation of p53 activity through lysine methylation. *Nature*. 2004; 432:353–360. [PubMed: 15525938]
30. Ivanov GS, Ivanova T, Kurash J, Ivanov A, Chuikov S, Gizatullin F, Herrera-Medina EM, Rauscher F 3rd, Reinberg D, Barlev NA. Methylation-acetylation interplay activates p53 in response to DNA damage. *Mol Cell Biol*. 2007; 27:6756–6769. [PubMed: 17646389]
31. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL. Repression of p53 activity by Smyd2-mediated methylation. *Nature*. 2006; 444:629–632. [PubMed: 17108971]
32. Shi X, Kachirskaja I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E, Gozani O. Modulation of p53 function by SET8-mediated methylation at lysine 382. *Mol Cell*. 2007; 27:636–646. [PubMed: 17707234]
33. Huang J, Dorsey J, Chuikov S, Perez-Burgos L, Zhang X, Jenuwein T, Reinberg D, Berger SL. G9a and Glp methylate lysine 373 in the tumor suppressor p53. *J Biol Chem*. 2010; 285:9636–9641. [PubMed: 20118233]
34. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhatter R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. *Nature*. 2007; 449:105–108. [PubMed: 17805299]
35. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. Two cellular proteins that bind to wild-type but not mutant p53. *Proc Natl Acad Sci U S A*. 1994; 91:6098–6102. [PubMed: 8016121]
36. Iwabuchi K, Li B, Massa HF, Trask BJ, Date T, Fields S. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. *J Biol Chem*. 1998; 273:26061–26068. [PubMed: 9748285]
37. Ea CK, Baltimore D. Regulation of NF-kappaB activity through lysine monomethylation of p65. *Proc Natl Acad Sci U S A*. 2009; 106:18972–18977. [PubMed: 19864627]
38. Levy D, Kuo AJ, Chang Y, Schaefer U, Kitson C, Cheung P, Espejo A, Zee BM, Liu CL, Tangsombatvisit S, Tennen RI, Kuo AY, Tanjing S, Cheung R, Chua KF, Utz PJ, Shi X, Prinjha RK, Lee K, Garcia BA, Bedford MT, Tarakhovsky A, Cheng X, Gozani O. Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling. *Nat Immunol*. 2011; 12:29–36. [PubMed: 21131967]
39. Chang Y, Levy D, Horton JR, Peng J, Zhang X, Gozani O, Cheng X. Structural basis of SETD6-mediated regulation of the NF-kB network via methyl-lysine signaling. *Nucleic Acids Res*. 2011; 39:6380–6389. [PubMed: 21515635]
40. Yang XD, Huang B, Li M, Lamb A, Kelleher NL, Chen LF. Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. *EMBO J*. 2009; 28:1055–1066. [PubMed: 19262565]
41. Lu T, Jackson MW, Wang B, Yang M, Chance MR, Miyagi M, Gudkov AV, Stark GR. Regulation of NF-kappaB by NSD1/FBXL11-dependent reversible lysine methylation of p65. *Proc Natl Acad Sci U S A*. 2010; 107:46–51. [PubMed: 20080798]
42. Zhang K, Lin W, Latham JA, Riefler GM, Schumacher JM, Chan C, Tatchell K, Hawke DH, Kobayashi R, Dent SY. The Set1 methyltransferase opposes Ipl1 aurora kinase functions in chromosome segregation. *Cell*. 2005; 122:723–734. [PubMed: 16143104]
43. Latham JA, Chosed RJ, Wang S, Dent SY. Chromatin signaling to kinetochores: transregulation of Dam1 methylation by histone H2B ubiquitination. *Cell*. 2011; 146:709–719. [PubMed: 21884933]
44. Gonsalvez, GB.; Matera, AG. in: *Posttranscriptional Gene Regulation*. Wiley-VCH Verlag GmbH & Co. KGaA; 2013. *Posttranslational Modification of Sm Proteins: Diverse Roles in snRNP Assembly and Germ Line Specification*; p. 83-116.
45. Moore KE, Carlson SM, Camp ND, Cheung P, James RG, Chua KF, Wolf-Yadlin A, Gozani O. A general molecular affinity strategy for global detection and proteomic analysis of lysine methylation. *Mol Cell*. 2013; 50:444–456. [PubMed: 23583077]
46. Bremang M, Cuomo A, Agresta AM, Stugiewicz M, Spadotto V, Bonaldi T. Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. *Mol Biosyst*. 2013; 9:2231–2247. [PubMed: 23748837]

47. Liu H, Galka M, Mori E, Liu X, Lin YF, Wei R, Pittock P, Voss C, Dhami G, Li X, Miyaji M, Lajoie G, Chen B, Li SS. A method for systematic mapping of protein lysine M. methylation identifies functions for HP1beta in DNA damage response. *Mol Cell*. 2013; 50:723–735. [PubMed: 23707759]
48. Cao XJ, Arnaudo AM, Garcia BA. Large-scale global identification of protein lysine methylation in vivo. *Epigenetics*. 2013; 8:477–485. [PubMed: 23644510]
49. Lhoest J, Lobet Y, Costers E, Colson C. Methylated proteins and amino acids in the ribosomes of *Saccharomyces cerevisiae*. *Eur J Biochem*. 1984; 141:585–590. [PubMed: 6378633]
50. Lobet Y, Lhoest J, Colson C. Partial purification and characterization of the specific protein-lysine N-methyltransferase of YL32, a yeast ribosomal protein. *Biochim Biophys Acta*. 1989; 997:224–231. [PubMed: 2504290]
51. Polevoda B, Sherman F. Methylation of proteins involved in translation. *Mol Microbiol*. 2007; 65:590–606. [PubMed: 17610498]
52. Porras-Yakushi TR, Whitelegge JP, Miranda TB, Clarke S. A novel SET domain methyltransferase modifies ribosomal protein Rpl23ab in yeast. *J Biol Chem*. 2005; 280:34590–34598. [PubMed: 16096273]
53. Porras-Yakushi TR, Whitelegge JP, Clarke S. Yeast ribosomal/cytochrome c SET domain methyltransferase subfamily: identification of Rpl23ab methylation sites and recognition motifs. *J Biol Chem*. 2007; 282:12368–12376. [PubMed: 17327221]
54. Porras-Yakushi TR, Whitelegge JP, Clarke S. A novel SET domain methyltransferase in yeast: Rkm2-dependent trimethylation of ribosomal protein L12ab at lysine 10. *J Biol Chem*. 2006; 281:35835–35845. [PubMed: 17005568]
55. Webb KJ, Laganowsky A, Whitelegge JP, Clarke SG. Identification of two SET domain proteins required for methylation of lysine residues in yeast ribosomal protein Rpl42ab. *J Biol Chem*. 2008; 283:35561–35568. [PubMed: 18957409]
56. Webb KJ, Al-Hadid Q, Zurita-Lopez CI, Young BD, Lipson RS, Clarke SG. The ribosomal 11 protuberance in yeast is methylated on a lysine residue catalyzed by a seven-beta-strand methyltransferase. *J Biol Chem*. 2011; 286:18405–18413. [PubMed: 21460220]
57. Williamson NA, Ralieghe J, Morrice NA, Wettenhall RE. Post-translational processing of rat ribosomal proteins. Ubiquitous methylation of Lys22 within the zinc-finger motif of RL40 (carboxy-terminal extension protein 52) and tissue-specific methylation of Lys4 in RL29. *Eur J Biochem*. 1997; 246:786–793. [PubMed: 9219540]
58. Van Noort JM, Kraal B, Sinjorgo KM, Persoon NL, Johanns ES, Bosch L. Methylation in vivo of elongation factor EF-Tu at lysine-56 decreases the rate of tRNA-dependent GTP hydrolysis. *Eur J Biochem*. 1986; 160:557–561. [PubMed: 3096728]
59. Lipson RS, Webb KJ, Clarke SG. Two novel methyltransferases acting upon eukaryotic elongation factor 1A in *Saccharomyces cerevisiae*. *Arch Biochem Biophys*. 2010; 500:137–143. [PubMed: 20510667]
60. Couttas TA, Raftery MJ, Padula MP, Herbert BR, Wilkins MR. Methylation of translation-associated proteins in *Saccharomyces cerevisiae*: Identification of methylated lysines and their methyltransferases. *Proteomics*. 2012; 12:960–972. [PubMed: 22522802]
61. Abu-Farha M, Lanouette S, Elisma F, Tremblay V, Butson J, Figeys D, Couture JF. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. *J Mol Cell Biol*. 2011; 3:301–308. [PubMed: 22028380]
62. Donlin LT, Andresen C, Just S, Rudensky E, Pappas CT, Kruger M, Jacobs EY, Unger A, Zieseniss A, Dobenecker MW, Voelkel T, Chait BT, Gregorio CC, Rottbauer W, Tarakhovskiy A, Linke WA. Smyd2 controls cytoplasmic lysine methylation of Hsp90 and myofilament organization. *Genes Dev*. 2012; 26:114–119. [PubMed: 22241783]
63. Cho HS, Shimazu T, Toyokawa G, Daigo Y, Maehara Y, Hayami S, Ito A, Masuda K, Ikawa N, Field HI, Tsuchiya E, Ohnuma S, Ponder BA, Yoshida M, Nakamura Y, Hamamoto R. Enhanced HSP70 lysine methylation promotes proliferation of cancer cells through activation of Aurora kinase B. *Nat Commun*. 2012; 3:1072. [PubMed: 22990868]
64. Jakobsson ME, Moen A, Bousset L, Egge-Jacobsen W, Kernstock S, Melki R, Falnes PO. Identification and Characterization of a Novel Human Methyltransferase Modulating Hsp70

- Protein Function through Lysine Methylation. *J Biol Chem.* 2013; 288:27752–27763. [PubMed: 23921388]
65. Cloutier P, Lavalleye-Adam M, Faubert D, Blanchette M, Coulombe B. A newly uncovered group of distantly related lysine methyltransferases preferentially interact with molecular chaperones to regulate their activity. *PLoS Genet.* 2013; 9:e1003210. [PubMed: 23349634]
 66. Trojer P, Li G, Sims RJ 3rd, Vaquero A, Kalakonda N, Boccuni P, Lee D, Erdjument-Bromage H, Tempst P, Nimer SD, Wang YH, Reinberg D. L3MBTL1, a histone-methylation-dependent chromatin lock. *Cell.* 2007; 129:915–928. [PubMed: 17540172]
 67. Li H, Fischle W, Wang W, Duncan EM, Liang L, Murakami-Ishibe S, Allis CD, Patel DJ. Structural basis for lower lysine methylation state-specific readout by MBT repeats of L3MBTL1 and an engineered PHD finger. *Mol Cell.* 2007; 28:677–691. [PubMed: 18042461]
 68. Min J, Allali-Hassani A, Nady N, Qi C, Ouyang H, Liu Y, MacKenzie F, Vedadi M, Arrowsmith CH. L3MBTL1 recognition of mono- and dimethylated histones. *Nat Struct Mol Biol.* 2007; 14:1229–1230. [PubMed: 18026117]
 69. Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. *Nat Struct Mol Biol.* 2007; 14:1025–1040. [PubMed: 17984965]
 70. Saddic LA, West LE, Aslanian A, Yates JR 3rd, Rubin SM, Gozani O, Sage J. Methylation of the retinoblastoma tumor suppressor by SMYD2. *J Biol Chem.* 2010; 285:37733–37740. [PubMed: 20870719]
 71. West LE, Roy S, Lachmi-Weiner K, Hayashi R, Shi X, Appella E, Kutateladze TG, Gozani O. The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. *J Biol Chem.* 2010; 285:37725–37732. [PubMed: 20870725]
 72. Nady N, Krichevsky L, Zhong N, Duan S, Tempel W, Amaya MF, Ravichandran M, Arrowsmith CH. Histone recognition by human malignant brain tumor domains. *J Mol Biol.* 2012; 423:702–718. [PubMed: 22954662]
 73. Kachirskaya I, Shi X, Yamaguchi H, Tanoue K, Wen H, Wang EW, Appella E, Gozani O. Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. *J Biol Chem.* 2008; 283:34660–34666. [PubMed: 18840612]
 74. Botuyan MV, Lee J, Ward IM, Kim JE, Thompson JR, Chen J, Mer G. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. *Cell.* 2006; 127:1361–1373. [PubMed: 17190600]
 75. Roy S, Musselman CA, Kachirskaya I, Hayashi R, Glass KC, Nix JC, Gozani O, Appella E, Kutateladze TG. Structural insight into p53 recognition by the 53BP1 tandem Tudor domain. *J Mol Biol.* 2010; 398:489–496. [PubMed: 20307547]
 76. Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature.* 2001; 410:120–124. [PubMed: 11242054]
 77. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. *Nature.* 2001; 410:116–120. [PubMed: 11242053]
 78. Jacobs SA, Taverna SD, Zhang Y, Briggs SD, Li J, Eissenberg JC, Allis CD, Khorasanizadeh S. Specificity of the HP1 chromo domain for the methylated N-terminus of histone H3. *EMBO J.* 2001; 20:5232–5241. [PubMed: 11566886]
 79. Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. *J Biol Chem.* 2001; 276:25309–25317. [PubMed: 11316813]
 80. Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H, Shinkai Y. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. *Genes Dev.* 2002; 16:1779–1791. [PubMed: 12130538]
 81. Sampath SC, Marazzi I, Yap KL, Krutchinsky AN, Mecklenbrauker I, Viale A, Rudensky E, Zhou MM, Chait BT, Tarakhovsky A. Methylation of a histone mimic within the histone

- methyltransferase G9a regulates protein complex assembly. *Mol Cell*. 2007; 27:596–608. [PubMed: 17707231]
82. Chin HG, Esteve PO, Pradhan M, Benner J, Patnaik D, Carey MF, Pradhan S. Automethylation of G9a and its implication in wider substrate specificity and HP1 binding. *Nucleic Acids Res*. 2007; 35:7313–7323. [PubMed: 17962312]
 83. Rathert P, Dhayalan A, Murakami M, Zhang X, Tamas R, Jurkowska R, Komatsu Y, Shinkai Y, Cheng X, Jeltsch A. Protein lysine methyltransferase G9a acts on non-histone targets. *Nat Chem Biol*. 2008; 4:344–346. [PubMed: 18438403]
 84. Islam K, Bothwell I, Chen Y, Sengelaub C, Wang R, Deng H, Luo M. Bioorthogonal profiling of protein methylation using azido derivative of S-adenosyl-L-methionine. *J Am Chem Soc*. 2012; 134:5909–5915. [PubMed: 22404544]
 85. Islam K, Chen Y, Wu H, Bothwell IR, Blum GJ, Zeng H, Dong A, Zheng W, Min J, Deng H, Luo M. Defining efficient enzyme-cofactor pairs for bioorthogonal profiling of protein methylation. *Proc Natl Acad Sci U S A*. 2013
 86. Pless O, Kowenz-Leutz E, Knoblich M, Lausen J, Beyermann M, Walsh MJ, Leutz A. G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. *J Biol Chem*. 2008; 283:26357–26363. [PubMed: 18647749]
 87. Trojer P, Zhang J, Yonezawa M, Schmidt A, Zheng H, Jenuwein T, Reinberg D. Dynamic Histone H1 Isotype 4 Methylation and Demethylation by Histone Lysine Methyltransferase G9a/KMT1C and the Jumonji Domain-containing JMJD2/KDM4 Proteins. *J Biol Chem*. 2009; 284:8395–8405. [PubMed: 19144645]
 88. Weiss T, Hergeth S, Zeissler U, Izzo A, Tropberger P, Zee BM, Dundr M, Garcia BA, Daujat S, Schneider R. Histone H1 variant-specific lysine methylation by G9a/KMT1C and Glp1/KMT1D. *Epigenetics Chromatin*. 2010; 3:7. [PubMed: 20334638]
 89. Lee JS, Kim Y, Kim IS, Kim B, Choi HJ, Lee JM, Shin HJ, Kim JH, Kim JY, Seo SB, Lee H, Binda O, Gozani O, Semenza GL, Kim M, Kim KI, Hwang D, Baek SH. Negative regulation of hypoxic responses via induced Reptin methylation. *Mol Cell*. 2010; 39:71–85. [PubMed: 20603076]
 90. Lee JS, Kim Y, Bhin J, Shin HJ, Nam HJ, Lee SH, Yoon JB, Binda O, Gozani O, Hwang D, Baek SH. Hypoxia-induced methylation of a pontin chromatin remodeling factor. *Proc Natl Acad Sci U S A*. 2011; 108:13510–13515. [PubMed: 21825155]
 91. Chang Y, Sun L, Kokura K, Horton JR, Fukuda M, Espejo A, Izumi V, Koomen JM, Bedford MT, Zhang X, Shinkai Y, Fang J, Cheng X. MPP8 mediates the interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase GLP/G9a. *Nat Commun*. 2011; 2:533. [PubMed: 22086334]
 92. Wu H, Chen X, Xiong J, Li Y, Li H, Ding X, Liu S, Chen S, Gao S, Zhu B. Histone methyltransferase G9a contributes to H3K27 methylation in vivo. *Cell Res*. 2011; 21:365–367. [PubMed: 21079650]
 93. Yu Y, Song C, Zhang Q, DiMaggio PA, Garcia BA, York A, Carey MF, Grunstein M. Histone H3 lysine 56 methylation regulates DNA replication through its interaction with PCNA. *Mol Cell*. 2012; 46:7–17. [PubMed: 22387026]
 94. Ling BM, Bharathy N, Chung TK, Kok WK, Li S, Tan YH, Rao VK, Gopinadhan S, Sartorelli V, Walsh MJ, Taneja R. Lysine methyltransferase G9a methylates the transcription factor MyoD and regulates skeletal muscle differentiation. *Proc Natl Acad Sci U S A*. 2012; 109:841–846. [PubMed: 22215600]
 95. Hirota T, Lipp JJ, Toh BH, Peters JM. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. *Nature*. 2005; 438:1176–1180. [PubMed: 16222244]
 96. Fischle W, Tseng BS, Dormann HL, Ueberheide BM, Garcia BA, Shabanowitz J, Hunt DF, Funabiki H, Allis CD. Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. *Nature*. 2005; 438:1116–1122. [PubMed: 16222246]
 97. Fischle W, Wang Y, Allis CD. Binary switches and modification cassettes in histone biology and beyond. *Nature*. 2003; 425:475–479. [PubMed: 14523437]
 98. Erce MA, Pang CN, Hart-Smith G, Wilkins MR. The methylproteome and the intracellular methylation network. *Proteomics*. 2012; 12:564–586. [PubMed: 22246820]

99. Hiatt WR, Garcia R, Merrick WC, Sypherd PS. Methylation of elongation factor 1 alpha from the fungus *Mucor*. *Proc Natl Acad Sci U S A*. 1982; 79:3433–3437. [PubMed: 6808511]
100. Clarke SG. Protein methylation at the surface and buried deep: thinking outside the histone box. *Trends Biochem Sci*. 2013; 38:243–252. [PubMed: 23490039]
101. Febbraio F, Andolfo A, Tanfani F, Briante R, Gentile F, Formisano S, Vaccaro C, Scire A, Bertoli E, Pucci P, Nucci R. Thermal stability and aggregation of *sulfolobus solfataricus* beta-glycosidase are dependent upon the N-epsilon-methylation of specific lysyl residues: critical role of in vivo post-translational modifications. *J Biol Chem*. 2004; 279:10185–10194. [PubMed: 14660666]
102. Chu Y, Zhang Z, Wang Q, Luo Y, Huang L. Identification and characterization of a highly conserved crenarchaeal protein lysine methyltransferase with broad substrate specificity. *J Bacteriol*. 2012; 194:6917–6926. [PubMed: 23086207]
103. Wang J, Hevi S, Kurash JK, Lei H, Gay F, Bajko J, Su H, Sun W, Chang H, Xu G, Gaudet F, Li E, Chen T. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. *Nat Genet*. 2009; 41:125–129. [PubMed: 19098913]
104. Esteve PO, Chin HG, Benner J, Feehery GR, Samaranyake M, Horwitz GA, Jacobsen SE, Pradhan S. Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. *Proc Natl Acad Sci U S A*. 2009; 106:5076–5081. [PubMed: 19282482]
105. Dhayalan A, Kudithipudi S, Rathert P, Jeltsch A. Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. *Chem Biol*. 2011; 18:111–120. [PubMed: 21276944]
106. Kudithipudi S, Dhayalan A, Kebede AF, Jeltsch A. The SET8 H4K20 protein lysine methyltransferase has a long recognition sequence covering seven amino acid residues. *Biochimie*. 2012; 94:2212–2218. [PubMed: 22583696]
107. Rathert P, Zhang X, Freund C, Cheng X, Jeltsch A. Analysis of the substrate specificity of the Dim-5 histone lysine methyltransferase using peptide arrays. *Chem Biol*. 2008; 15:5–11. [PubMed: 18215768]
108. Levy D, Liu CL, Yang Z, Newman AM, Alizadeh AA, Utz PJ, Gozani O. A proteomic approach for the identification of novel lysine methyltransferase substrates. *Epigenetics Chromatin*. 2011; 4:19. [PubMed: 22024134]
109. Zhang Y, Wolf-Yadlin A, Ross PL, Pappin DJ, Rush J, Lauffenburger DA, White FM. Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. *Mol Cell Proteomics*. 2005; 4:1240–1250. [PubMed: 15951569]
110. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science*. 2009; 325:834–840. [PubMed: 19608861]
111. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, Harper JW, Gygi SP. Systematic and quantitative assessment of the ubiquitin-modified proteome. *Mol Cell*. 2011; 44:325–340. [PubMed: 21906983]
112. Ong SE, Mittler G, Mann M. Identifying and quantifying in vivo methylation sites by heavy methyl SILAC. *Nat Methods*. 2004; 1:119–126. [PubMed: 15782174]
113. Lee BW, Sun HG, Zang T, Kim BJ, Alfaro JF, Zhou ZS. Enzyme-catalyzed transfer of a ketone group from an S-adenosylmethionine analogue: a tool for the functional analysis of methyltransferases. *J Am Chem Soc*. 2010; 132:3642–3643. [PubMed: 20196537]
114. Peters W, Willnow S, Duisken M, Kleine H, Macherey T, Duncan KE, Litchfield DW, Luscher B, Weinhold E. Enzymatic site-specific functionalization of protein methyltransferase substrates with alkynes for click labeling. *Angew Chem Int Ed Engl*. 2010; 49:5170–5173. [PubMed: 20572224]
115. Binda O, Boyce M, Rush JS, Palaniappan KK, Bertozzi CR, Gozani O. A chemical method for labeling lysine methyltransferase substrates. *Chembiochem*. 2011; 12:330–334. [PubMed: 21243721]

116. Islam K, Zheng W, Yu H, Deng H, Luo M. Expanding cofactor repertoire of protein lysine methyltransferase for substrate labeling. *ACS Chem Biol.* 2011; 6:679–684. [PubMed: 21495674]
117. Agard NJ, Prescher JA, Bertozzi CR. A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems. *J Am Chem Soc.* 2004; 126:15046–15047. [PubMed: 15547999]
118. Bishop AC, Ubersax JA, Petsch DT, Matheos DP, Gray NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO, Shokat KM. A chemical switch for inhibitor-sensitive alleles of any protein kinase. *Nature.* 2000; 407:395–401. [PubMed: 11014197]
119. Bishop A, Buzko O, Heyeck-Dumas S, Jung I, Kraybill B, Liu Y, Shah K, Ulrich S, Witucki L, Yang F, Zhang C, Shokat KM. Unnatural ligands for engineered proteins: new tools for chemical genetics. *Annu Rev Biophys Biomol Struct.* 2000; 29:577–606. [PubMed: 10940260]
120. Shinkai Y, Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. *Genes Dev.* 2011; 25:781–788. [PubMed: 21498567]
121. Luo M. Current chemical biology approaches to interrogate protein methyltransferases. *ACS Chem Biol.* 2012; 7:443–463. [PubMed: 22220966]
122. Petrossian TC, Clarke SG. Uncovering the human methyltransferasome. *Mol Cell Proteomics.* 2011; 10:M110–000976. [PubMed: 20930037]
123. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. *Nat Rev Genet.* 2012; 13:343–357. [PubMed: 22473383]
124. Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. *Nat Rev Mol Cell Biol.* 2012; 13:297–311. [PubMed: 22473470]
125. Pradhan S, Chin HG, Esteve PO, Jacobsen SE. SET7/9 mediated methylation of non-histone proteins in mammalian cells. *Epigenetics.* 2009; 4:383–387. [PubMed: 19684477]
126. Li Y, Trojer P, Xu CF, Cheung P, Kuo A, Drury WJ 3rd, Qiao Q, Neubert TA, Xu RM, Gozani O, Reinberg D. The target of the NSD family of histone lysine methyltransferases depends on the nature of the substrate. *J Biol Chem.* 2009; 284:34283–34295. [PubMed: 19808676]
127. Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, Garcia BA, Li W, Gozani O. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. *Mol Cell.* 2011; 44:609–620. [PubMed: 22099308]
128. Wigle TJ, Copeland RA. Drugging the human methylome: an emerging modality for reversible control of aberrant gene transcription. *Curr Opin Chem Biol.* 2013; 17:369–378. [PubMed: 23619004]
129. Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, Zhang Y. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. *Mol Cell.* 2001; 8:1207–1217. [PubMed: 11779497]
130. Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P, Reinberg D. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. *Genes Dev.* 2002; 16:479–489. [PubMed: 11850410]
131. Lehnertz B, Rogalski JC, Schulze FM, Yi L, Lin S, Kast J, Rossi FM. p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. *Mol Cell.* 2011; 43:673–680. [PubMed: 21855805]
132. Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, Testa G. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. *Mol Cell.* 2011; 43:681–688. [PubMed: 21855806]
133. Matthews AG, Kuo AJ, Ramon-Maiques S, Han S, Champagne KS, Ivanov D, Gallardo M, Carney D, Cheung P, Ciccone DN, Walter KL, Utz PJ, Shi Y, Kutateladze TG, Yang W, Gozani O, Oettinger MA. RAG2 PHD finger couples histone H3 lysine 4 trimethylation with V(D)J recombination. *Nature.* 2007; 450:1106–1110. [PubMed: 18033247]
134. Chang PY, Hom RA, Musselman CA, Zhu L, Kuo A, Gozani O, Kutateladze TG, Cleary ML. Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL-dependent gene transcription. *J Mol Biol.* 2010; 400:137–144. [PubMed: 20452361]

135. Shi X, Kachirskaja I, Walter KL, Kuo JH, Lake A, Davrazou F, Chan SM, Martin DG, Fingerma IM, Briggs SD, Howe L, Utz PJ, Kutateladze TG, Lugovskoy AA, Bedford MT, Gozani O. Proteome-wide analysis in *Saccharomyces cerevisiae* identifies several PHD fingers as novel direct and selective binding modules of histone H3 methylated at either lysine 4 or lysine 36. *J Biol Chem.* 2007; 282:2450–2455. [PubMed: 17142463]
136. Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. *Annu Rev Biochem.* 2012; 81:65–95. [PubMed: 22663077]
137. Varier RA, Timmers HT. Histone lysine methylation and demethylation pathways in cancer. *Biochim Biophys Acta.* 2011; 1815:75–89. [PubMed: 20951770]

Highlights

- Lysine methylation regulates the activity of key non-histone proteins
- Recently-developed methods have revealed significant proteome-wide methylation
- Lysine methylation represents a key signaling process in the nucleus and cytoplasm

Figure 1. Examples of methylation signaling pathways

A. Methylation signaling via H3K4me3. Trimethylation of H3K4 by the SET1 family of KMTs leads to recognition of the methylated histone by PHD finger-containing proteins and downstream regulation of transcription and V(D)J recombination [133-135] (reviewed in [69, 123, 136, 137]). This methylation mark is removed by JARID1 family of demethylases (reviewed in [123, 124, 137]). **B.** Methylation signaling via p53K370 methylation. p53 is monomethylated at lysine 370 by Smyd2 [31]. Dimethylation by an unknown methyltransferase recruits 53BP1 and regulates transcription [34]. These methyl marks can be removed by LSD1 [34]. **C.** Methylation signaling via RelAK310me1. SETD6 catalyzes addition of one methyl group to lysine 310 of the NF-κB subunit RelA [38]. This mark is recognized by GLP and leads to tonic repression of target genes [38, 39]. GLP binding is inhibited by phosphorylation of an adjacent serine residue [38, 39]. **D.** Methylation signaling

via MCM4K216me1. Monomethylation of the replication licensing factor MCM4 at lysine 216 was identified in a proteomic screen for methylated proteins [45]. The writer, reader, eraser, and function of this mark are unknown; it provides an example of methylation for which the signaling pathway has not yet been established.

Table 1

Comparison of methods for proteomic analysis of lysine methylation

Method	Pros	Cons	References
Peptide array	<ul style="list-style-type: none"> • Generate consensus methylation sequence • Relative simplicity of <i>in vitro</i> method 	<ul style="list-style-type: none"> • Non-physiological • Enzymes may require cofactors not present <i>in vitro</i> • Not all enzymes methylate peptides 	[83, 105-107]
Protein array	<ul style="list-style-type: none"> • Full-length protein represented • Relative simplicity of <i>in vitro</i> method 	<ul style="list-style-type: none"> • Non-physiological • Enzymes may require cofactors not present <i>in vitro</i> • Missing, incomplete, or incorrectly folded proteins 	[108]
Pan-methyl antibody- MS	<ul style="list-style-type: none"> • <i>In vivo</i> biological methylation • Mass spectrometry analysis 	<ul style="list-style-type: none"> • Current commercially-available antibodies unreliable • Polyclonal antibodies difficult to independently replicate 	[46, 48, 112]
Domain affinity-MS	<ul style="list-style-type: none"> • <i>In vivo</i> biological methylation • Reproducible, engineerable monoclonal affinity reagent • Mass spectrometry analysis 	<ul style="list-style-type: none"> • Protein, rather than peptide, pull-down identifies fewer PTM sites directly 	[45, 47]
Chemical affinity (click)-MS	<ul style="list-style-type: none"> • <i>In vivo</i> biological methylation • Mass spectrometry analysis 	<ul style="list-style-type: none"> • Enzyme must accept functionalized cofactor 	[84, 85]